developed a TanCAR specific to two glioma-associated antigens, HER2 and IL13Rα2, and found that TanCAR-T cells could simultaneously engage both antigens by inducing HER2-IL13Rα2 heterodimers, which promoted superadditive T cell activation when both antigens were encountered concurrently. The gene discussed is ERBB2; the disease is central nervous system cancer.